Physician profile
Syed U Ali
NPI 1982997342
$17,414.40
in general payments reported to CMS, 2019-2025
28 companies · $1,504 in 2025
The $1,504 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,818 · 2020: $3,536 · 2021: $733 · 2022: $1,586 · 2023: $4,226 · 2024: $3,012 · 2025: $1,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,761 · Food and Beverage: $3,927 · Education: $54.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,760.83 |
| Food and Beverage | $3,926.68 |
| Education | $54.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,409.76 | 2021-2025 | Advisa Dr Mri Surescan, Corevalve Evolut R, Micra |
| Medtronic USA, INC. | $3,333.33 | 2020 | |
| Abbott Laboratories | $2,256.93 | 2020-2024 | Optis, Pressurewire, Xience Sierra |
| Edwards Lifesciences Corporation | $2,253.38 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $367.35 | 2023-2025 | |
| Medtronic Vascular, INC. | $325.90 | 2019-2020 | |
| Novo Nordisk INC | $306.59 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $281.42 | 2023-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $218.95 | 2023 | Verquvo |
| Boston Scientific Corporation | $215.87 | 2019 | |
| Intuitive Surgical, INC. | $175.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $162.01 | 2023-2024 | Eliquis, Camzyos |
| Abiomed | $155.81 | 2022-2024 | Impella |
| Alnylam Pharmaceuticals INC. | $150.00 | 2025 | Amvuttra |
| Lilly USA, LLC | $108.79 | 2024 | Mounjaro |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.92 | 2023-2024 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $96.04 | 2024 | Arcalyst |
| Inspire Medical Systems, INC. | $90.29 | 2023 | Inspire |
| Pfizer INC. | $89.50 | 2022 | |
| Amgen INC. | $67.70 | 2023-2024 | Repatha |
| Scpharmaceuticals INC. | $61.03 | 2023 | |
| Becton, Dickinson and Company | $60.62 | 2025 | Lutonix Drug Coated Balloon, Ultraverse 014 |
| Novartis Pharmaceuticals Corporation | $39.45 | 2024-2025 | |
| Daiichi Sankyo INC. | $25.94 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $23.81 | 2023 | Evkeeza |
| Amarin Pharma, INC. | $23.57 | 2023 | |
| Shockwave Medical, INC | $12.01 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.